We embrace innovative approaches to clinical development.
Our programs focus on innovations that have the potential to deliver highly impactful therapies for unmet medical needs and drive differentiated therapeutic benefits for patients.
A Phase 1/1b Combination Study of Paclitaxel with BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients with Advanced Nonhematologic Malignancies
Therapeutic area: Oncology
Study ID #: NCT03328494
A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
Therapeutic area: Autoimmune
Study ID #: NCT03036865
For more information on our trials, visit www.clinicaltrials.gov